These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 26784451

  • 21. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
    Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H.
    Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
    [Abstract] [Full Text] [Related]

  • 22. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
    Koo DH, Park I, Ahn JH, Lee DH, You D, Jeong IG, Song C, Hong B, Hong JH, Ahn H, Lee JL.
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
    [Abstract] [Full Text] [Related]

  • 23. [Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
    Sikic D, Lüdecke G, Lieb V, Keck B.
    Urologe A; 2016 May; 55(5):648-52. PubMed ID: 27119958
    [Abstract] [Full Text] [Related]

  • 24. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Wong MK, Jarkowski A.
    Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
    [Abstract] [Full Text] [Related]

  • 25. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
    Breaker K, Naam M, La Rosa FG, Flaig IP, Flaig TW.
    Dermatol Surg; 2013 Jul; 39(7):981-7. PubMed ID: 23464361
    [Abstract] [Full Text] [Related]

  • 26. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H, Imai S, Harada K, Fujisawa M.
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
    Sulkes A.
    Isr Med Assoc J; 2010 Oct; 12(10):628-32. PubMed ID: 21090521
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
    Santoni M, Conti A, De Giorgi U, Iacovelli R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D, Cascinu S.
    Int J Cancer; 2014 Aug 15; 135(4):763-73. PubMed ID: 24127298
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
    Rini BI, Choueiri TK, Elson P, Khasawneh MK, Cotta C, Unnithan J, Wood L, Mekhail T, Garcia J, Dreicer R, Bukowski RM.
    Cancer; 2008 Sep 15; 113(6):1309-14. PubMed ID: 18618496
    [Abstract] [Full Text] [Related]

  • 34. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
    Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E.
    BJU Int; 2011 Oct 15; 108(8 Pt 2):E250-7. PubMed ID: 21599821
    [Abstract] [Full Text] [Related]

  • 35. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Fiorio Pla A, Brossa A, Bernardini M, Genova T, Grolez G, Villers A, Leroy X, Prevarskaya N, Gkika D, Bussolati B.
    BMC Cancer; 2014 Dec 12; 14():939. PubMed ID: 25494980
    [Abstract] [Full Text] [Related]

  • 36. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep 12; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 37. Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.
    Laurila JP, Laukkanen MO, Joensuu H, Salmi M, Jalkanen S.
    Int J Cancer; 2016 Nov 15; 139(10):2270-6. PubMed ID: 27459381
    [Abstract] [Full Text] [Related]

  • 38. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA.
    J Clin Oncol; 2008 Aug 20; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract] [Full Text] [Related]

  • 39. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
    Sugiyama M, Fujita K, Murayama N, Akiyama Y, Yamazaki H, Sasaki Y.
    Drug Metab Dispos; 2011 May 20; 39(5):757-62. PubMed ID: 21266595
    [Abstract] [Full Text] [Related]

  • 40. Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
    Derbel Miled O, Dionne C, Terret C, Segura-Ferlay C, Flechon A, Neidhart EM, Negrier S, Droz JP.
    J Geriatr Oncol; 2013 Jul 20; 4(3):255-61. PubMed ID: 24070463
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.